Intranasal Immunization with CTL Epitope Peptides from HIV-1 or Ovalbumin and the Mucosal Adjuvant Cholera Toxin Induces Peptide-Specific CTLs and Protection Against Tumor Development in Vivo

Journal of Immunology

Volumn 158, Issue 2, 1997, Pages 834-841

  Porgador, Angel ^a   Staats, Herman F ^a,b   Faiola, Brenda ^a   Gilboa, Eli ^a   Palker, Thomas J ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; EPITOPE; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305 321); HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOLOGICAL ADJUVANT; OVALBUMIN; PEPTIDE FRAGMENT;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CHOLERA TOXIN; EPITOPES; FEMALE; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031567923     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Lynch, D. H., and R. E. Miller. 1991. Immunotherapeutic elimination of syngeneic tumors in vivo hy cytotoxic T lymphocytes generated in vitro from lymphocytes from the drainine lymph nodes of tumor-bearins mice. Eur. J. Immunol. 21:1401.
2. Porgador, A., E. Tzehoval, A. Katz, E. Vadai, M. Revel, M. Feldman, and L. Eisenbach. 1992. Imerleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52:3679.
3. Porgador. A., R. Bannerji, Y. Watanabe, M. Feldman, E. Gilboa, and L. Eisenbach. 1993. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted lumor cells. J. Immunol. 150:1458.
4. Porgador, A., E. Tzehoval, E. Vadai, M. Feldman, and L. Eisenbach. 1993. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or inerferon-gamma genes. J. Immunother. 14:191.
5. Zhou, F., and L. Huang. 1994. Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC Class I-restricted antigen presentation pathway. Immunomethods 4:229.
6. Zhou, F., S. C. Watkins, and L. Huang. 1994. Characterization and kinetics of MHC class I-restricted presentation of a soluble antigen delivered by liposomes. Immunobiology 190:35.
7. Martin, S., G. Niedermann, C, Leipner, K. Eichmann, and H. Weltzien. 1993. Intracellular processing of hapten-modificd protein for MHC class I presentation: cytoplasmic delivery by pH-sensitive liposomes, Immunol. Lett. 37:97.
8. Zhou, F., B. T. Rouse, and L. Huang. 1992. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J. Immunol. 149:1599.
9. Reddy, R., F. Zhou, S. Nair, L. Huang, and B. T. Rouse, 1992. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol. 148:1585.
10. 4-Independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens. Int. lmmunol. 7:1205.
11. Nehete, P. N., K. S. Casement, R. B. Arlinghaus, and K. H. Sastry. 1995. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes hy synthetic peptides from the V3 loop region of HIV-1 IIIB gp120. Cell. Immunol. 160:217.
12. + cytotoxic T lymphocytes in rhesus monkeys. J. lmmunol. 151: 5096.
13. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope-darived peptide-pulsed dendritic cells. Int. Immunol. 5:84.
14. Poragdor, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
15. Kilian, M., and M. W. Russell. 1994. Function of mucosal immunoglobulins. In Handbook of Mucosal Immunology. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, and J. Bienenstock, eds. Academic Press, San Diego, p. 127.
16. London, S. D. 1994. Cytotoxic lymphocytes in mucosal effector sites. In Handbook of Mucosal Immunology. P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. R. McGhee, and J. Bienenstock, eds. Academic Press, San Diego, p. 325.
17. Mowat, A. M. 1994. Oral tolerance and regulation of immunity to dietary antigens. In Handbook of Mucosal Immunology. P. L. Ogra, M. E. Lamm, J. R. McGhee, J. Mestecky, W. Strober, and J. Bienenstock, eds. Academic Press, San Diego, p. 185.
18. Elson, C. O., and M. T. Dertzbaugh. 1994. Mucosal adjuvants. In Handbook of Mucosal Immunology. P. L. Ogra, M. E. Lamm, J. R. McGhee, J. Mestecky, W. Strober, and J. Bienenstock, eds. Academic Press. San Diego, p. 391.
19. Staats, H. F., R. J. Jackson, M. Marinaro, I. Takahashi, H. Kiyono, and J. R. McGhee. 1994. Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immunol. 6:572.
20. Jackson, R. J., K. Fujihashi, J. Xu-Amano, H. Kiyono, C. O. Elson, and J. R. McGhee. 1993. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 61:4272.
21. Wu, H. Y., and M. W. Russell. 1993. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 61:314.
22. Bowen, J. C., S. K. Nair, R. Reddy, and B. T. Rouse. 1994. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology 81:338.
23. Mandelboim, O., G. Berke, M. Fridkin, M. Feldman, M. Eisenstein, and L. Eisenbach. 1994. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67.
24. Staats, H. F., W. G. Nichols, and T. J. Palker. 1996. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. lmmunol. 157:462.
25. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing presentation. Cell 54:777.
26. Rotzschke, O., K. Falk, S. Stevanovic, G. Jung, P. Waiden, and H. G. Rammensee. 1991. Exact prediction of a natural T cell epitope. Eur. J. lmmunol. 21:2891.
27. Casement, K. S., P. N. Nehete, R. B. Arlinghaus, and K. J. Sastry. 1995. Crossreactive cytotoxic t lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1. Virology 211:261.
28. Volgmann, T., A. Klein-Struckmeier. and H. Mohr. 1989. A fluorescence-based assay for quantitation of lymphokine-activated killer activity. J. lmmunol. Methods 119:45.
29. Miedema, F., and M. R. Klein. 1996. AIDS pathogenesis: a finite immune response to blame? Science 272:505.
30. Haynes, B. F., G. Pantaleo, and A. S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324.
31. Strominger, J. L. 1995. Peptide vaccination against cancer? Nat. Med. 1:1179.
32. Sarkar, M. A. 1992. Drug metabolism in the nasal mucosa. Pharmacol. Res. 9:1.
33. Kliks, S. C., T. Shioda, N. L. Haigwood, and J. Levy. 1993. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:11518.
34. Lasarte, J. J., P. Sarobe, A. Gullon, J. Prieto, and F. Borras-Cuesta. 1992. Induction of cytoloxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell. lmmunol. 141:211.
35. + cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120. Virology 118:502.
36. + cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc. Natl. Acad. Sci. USA 88:9448.
37. Walker, C., M. Selby, A. Erickson, D. Cataldo, J. P. Valensi, and C. V. Van Nest. 1992. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc. Natl, Acad. Sci. USA 89: 7915.
38. Lynch, D. H., A. E. Namen, and R. E. Miller. 1991. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur. J. Immunol. 21:2977.
39. Zatloukal, K., A. Schneeberger, M. Berger. W. Schmidt, F. Koszik, R. Kutil, M. Cotten, E. Wagner, M. Buschle, G. Maass, E. Payer, G. Stingl, and M. L. Birnstiel. 1995. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine: assessment of critical cellular and molecular parameters. J. Immunol. 154:3406.
40. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
41. Mandelboim, O., E. Vadai, M. Fridkin, A. Katz-Hillel, M. Feldman, G. Berke, and L. Eisenbach. 1995. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1:1179.
42. Bromander, A. K., M. Kjerrulf, J. Holmgren, and N. Lycke. 1993. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand. J. Immunol. 37:452.
43. McGee, D. W., C. O. Elson, and J. R. McGhee. 1993. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect. Immun. 61:4637.
44. Bromander, A., J. Holmgren, and N. Lycke. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. lmmunol. 146:2908.
45. Schuerer-Maly, C. C., L. Eckman, M. F. Kagnoff, M. T. Falco, and F. E. Maly. 1994. Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology 81:85.
46. Hornquist, E., and N. Lycke. 1993. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23:2136.
47. Clarke, C. J., A. D. Wilson, N. A. Williams, and C. R. Stokes. 1991. Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant. Immunology 72:323.
48. Lycke, N., U. Karlsson, A. Sjolander, and K. E. Magnusson. 1991. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand. J. Immunol. 33:691.
49. Hashigucci, K., H. Ogawa, T. Ishidate, R. Yamashita, H. Kamiya, K. Watanabe, N. Hattori, T. Sato, Y. Suzuki, T. Nagamine, C. Aizawa, S. Tamura, T. Kurata, and A. Ova. 1996. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia colt heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14:113.
50. Roberts, M., A. Bacon, R. Rappuoli, M. Pizza, I. Cropley, G. Douce, G. Dougan, M. Marinaro, J. McGhee, and S. Chatfield. 1995. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect. Immun. 63:2100.
51. Fontana, M. R., R. Manetti, V. Ciannelli, C. Magagnoli, A. Marchini, R. Olivieri, M. Domenighini, R. Rappuoli, and M. Pizza. 1995. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:2356.
52. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617.
53. Carbone, F., and M. J. Bevan. 1989. Induction of ovalbumin-specific cytotoxic T cells by in vivo immunization. J. Exp. Med. 169:603.
54. Ishioka, G. Y., S. Colon, C. Miles, H. M. Grey, and R. W. Chesnut. 1989. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo. J. Immunol. 143:1094.
55. Russell, M. W., Z. Moldoveanu, P. L. White, G. J. Sibert, J. Mestecky, and S. M. Michalek. 1996. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit, Infecl. Immun. 64:1272.
56. Disis, M. L., J. R. Gralow, H. Bernhard, S. L. Hand, W. D. Rubin, and M. A. Cheever. 1996. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J. Immunol. 156:3151.